CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
LY3009104 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01247350
NCT01247350Phase 1Completed

A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects

Eli Lilly and Company·interventional·Posted Nov 24, 2010·Updated Apr 13, 2018

In Brief

A Phase 1 clinical trial evaluating LY3009104 and Placebo for Healthy Volunteer. Completed, enrolled 34 participants across 1 site.

Detailed Summary

To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple doses in Japanese healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 24, 2010
Enrollment StartNov 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.6 years ago

Interventions

LY3009104drug

Administered orally

Placebodrug

Administered orally